GlobeNewsWire
05 Jul 2026, 15:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of using channel stuffing to report 20% revenue growth in 2025 when real growth was allegedly -3%. — Allegations of systemic revenue inflation and fraudulent growth metrics typically lead to severe valuation corrections and loss of investor trust.
-0.80A federal securities class action lawsuit has been filed against ADMA Biologics alleging violations of federal securities laws. — Class action lawsuits create significant legal liabilities, potential settlements, and long-term reputational damage.
-0.60The company is alleged to have engaged in undisclosed related party transactions and lacked adequate internal controls. — Deficiencies in internal controls and undisclosed related-party deals suggest poor corporate governance and a higher risk of further accounting irregularities.
-0.50Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a federal securities class action lawsuit alleging fraud, channel stuffing, and lack of internal controls.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
